Federated Hermes
NKTR icon

Federated Hermes’s Nektar Therapeutics NKTR Stock Holding History

Federated Hermes’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-84
Closed -$1.17K – 2153
2024
Q4 		$1.17K Hold
84
– – ﹤0.01% 2011
2024
Q3 		$1.63K Hold
84
– – ﹤0.01% 1948
2024
Q2 		$1.56K Hold
84
– – ﹤0.01% 1917
2024
Q1 		$1.17K Hold
84
– – ﹤0.01% 1952
2023
Q4 		$710 Sell
84
-28
-25% -$212 ﹤0.01% 1997
2023
Q3 		$998 Sell
112
-49,706
-100% -$478K ﹤0.01% 2006
2023
Q2 		$430K Sell
49,818
-76,901
-61% -$820K ﹤0.01% 1417
2023
Q1 		$1.34M Buy
126,719
+3,192
+3% +$96.6K ﹤0.01% 1081
2022
Q4 		$4.19M Buy
123,527
+67,723
+121% +$3.28M 0.01% 717
2022
Q3 		$2.68M Buy
55,804
+48,605
+675% +$2.89M 0.01% 831
2022
Q2 		$410K Buy
+7,199
New +$454K ﹤0.01% 1408
2021
Q4 		– Sell
-1,364
Closed -$368K – 2272
2021
Q3 		$368K Sell
1,364
-87
-6% -$20.9K ﹤0.01% 1571
2021
Q2 		$374K Sell
1,451
-271
-16% -$75K ﹤0.01% 1575
2021
Q1 		$517K Sell
1,722
-11
-0.6% -$3.42K ﹤0.01% 1557
2020
Q4 		$442K Sell
1,733
-294
-15% -$76K ﹤0.01% 1544
2020
Q3 		$504K Sell
2,027
-971
-32% -$305K ﹤0.01% 1470
2020
Q2 		$1.04M Sell
2,998
-5,565
-65% -$1.74M ﹤0.01% 1233
2020
Q1 		$2.29M Sell
8,563
-59,739
-87% -$18.5M 0.01% 852
2019
Q4 		$22.1M Sell
68,302
-35,171
-34% -$10.2M 0.05% 387
2019
Q3 		$28.3M Buy
103,473
+103,034
+23,470% +$37.8M 0.07% 286
2019
Q2 		$235K Sell
439
-5
-1% -$2.51K ﹤0.01% 1537
2019
Q1 		$224K Buy
444
+12
+3% +$7.11K ﹤0.01% 1546
2018
Q4 		$213K Sell
432
-21,505
-98% -$13M ﹤0.01% 1549
2018
Q3 		$20.1M Sell
21,937
-9
-0% -$7.68K 0.05% 349
2018
Q2 		$16.1M Sell
21,946
-15,661
-42% -$18.1M 0.05% 311
2018
Q1 		$59.9M Sell
37,607
-47,707
-56% -$61.5M 0.17% 113
2017
Q4 		$76.4M Buy
85,314
+16,767
+24% +$9.92M 0.22% 95
2017
Q3 		$24.7M Sell
68,547
-4,720
-6% -$1.48M 0.07% 225
2017
Q2 		$21.5M Buy
73,267
+1,327
+2% +$383K 0.06% 258
2017
Q1 		$25.3M Buy
71,940
+3,653
+5% +$821K 0.07% 232
2016
Q4 		$12.6M Hold
68,287
– – 0.04% 366
2016
Q3 		$17.6M Sell
68,287
-52,900
-44% -$13.6M 0.05% 290
2016
Q2 		$25.9M Buy
121,187
+1,516
+1% +$339K 0.08% 212
2016
Q1 		$24.7M Sell
119,671
-138,924
-54% -$26.7M 0.08% 222
2015
Q4 		$65.4M Buy
258,595
+19,690
+8% +$4.05M 0.21% 98
2015
Q3 		$39.3M Buy
238,905
+445
+0.2% +$78.7K 0.13% 162
2015
Q2 		$44.7M Sell
238,460
-44,845
-16% -$7.72M 0.13% 164
2015
Q1 		$46.7M Sell
283,305
-49,042
-15% -$10.1M 0.14% 149
2014
Q4 		$77.3M Sell
332,347
-59,066
-15% -$12.6M 0.24% 81
2014
Q3 		$70.9M Sell
391,413
-2,643
-0.7% -$506K 0.23% 89
2014
Q2 		$75.8M Sell
394,056
-31,544
-7% -$5.58M 0.24% 79
2014
Q1 		$77.4M Buy
425,600
+75,558
+22% +$15M 0.26% 75
2013
Q4 		$59.6M Sell
350,042
-9,876
-3% -$1.59M 0.21% 101
2013
Q3 		$56.4M Sell
359,918
-56,649
-14% -$10.5M 0.22% 99
2013
Q2 		$72.2M Buy
+416,567
New +$63.9M 0.29% 73

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Federated Hermes's NKTR Position: Q1 2025 in Review

Federated Hermes sold out of Nektar Therapeutics (NKTR) in Q1 2025, closing a stake of 84 shares — an estimated $1.17K sold.

Federated Hermes first reported a position in NKTR in Q2 2013 and held it in 45 quarters. The position peaked at $77.4M in Q1 2014. 154 funds tracked by Wall St. Rank hold NKTR as of Q1 2025.

  • Federated Hermes reported no remaining Nektar Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Federated Hermes sold 84 Nektar Therapeutics shares in Q1 2025, an estimated $1.17K.
  • Federated Hermes first reported a position in Nektar Therapeutics in Q2 2013 and held it in 45 quarters.
  • Federated Hermes's Nektar Therapeutics position peaked at $77.4M in Q1 2014.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2025.

Based on Federated Hermes's 13F filing for Q1 2025, filed 8 May 2025.